Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

BACKGROUND: CTLA4 blocking monoclonal antibodies provide a low frequency but durable tumor responses in patients with metastatic melanoma, which led to the regulatory approval of ipilimumab based on two randomized clinical trials with overall survival advantage. The similarly fully human anti-CTLA4...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Ribas, Antoni, Chesney, Jason A, Gordon, Michael S, Abernethy, Amy P, Logan, Theodore F, Lawson, David H, Chmielowksi, Bartosz, Glaspy, John A, Lewis, Karl, Huang, Bo, Wang, Erjian, Hsyu, Poe-Hirr, Gomez-Navarro, Jesus, Gerhardt, Diana, Marshall, Margaret A, Gonzalez, Rene
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2012
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3543342/
https://ncbi.nlm.nih.gov/pubmed/23171508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-10-236
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים